Literature DB >> 19952026

Cystic fibrosis genotype and assessing rates of decline in pulmonary status.

Robert H Cleveland1, David Zurakowski, Dubhfeasa Slattery, Andrew A Colin.   

Abstract

PURPOSE: To evaluate the hierarchical phenotypic expression of cystic fibrosis transmembrane conductance regulator (CFTR) genotypes in the respiratory system as has been documented in the pancreas.
MATERIALS AND METHODS: This study was institutional review board approved; informed consent was not required. HIPAA guidelines were followed. Genotype effects were assessed by using chest radiographic and pulmonary function test (PFT) results in 93 patients. Serial chest radiographic and PFT (percentage of predicted forced expiratory volume in 1 second [FEV(1)], percentage of predicted forced vital capacity [FVC]) results were compared by using analysis of variance with repeated measures. By using CFTR class of mutations, two groups were created: group S (severe disease) and group M (mild disease). Within group S, three subgroups were created: A consisted of patients with two class I alleles; B, class I allele and class II or III allele; C, class II allele and class II or III allele. Group M consisted of patients with at least one allele from class IV-VI.
RESULTS: Within group S, subgroup A had a faster deterioration than B or C according to radiographic data (A vs B, P = .014; A vs C, P = .009), with only a borderline difference in FEV(1) for subgroups A versus C (P = .031). Otherwise, PFTs were not sensitive for distinguishing subgroups. Only radiographic results identified that subgroup B had faster progression than C (P = .003); all parameters had trends of decline in the same direction. Group S had a faster decline than group M (radiography, P = .005; FVC, P = .011; FEV(1), P = .529).
CONCLUSION: Disease progressed more rapidly with gene class hierarchical correlations seen in pancreatic disease. Radiography was more sensitive for identifying differences.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952026     DOI: 10.1148/radiol.2533090418

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

1.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

2.  Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis.

Authors:  Chi Wang; Irina Protasevich; Zhengrong Yang; Derek Seehausen; Timothy Skalak; Xun Zhao; Shane Atwell; J Spencer Emtage; Diana R Wetmore; Christie G Brouillette; John F Hunt
Journal:  Protein Sci       Date:  2010-10       Impact factor: 6.725

3.  Similar performance of Brasfield and Wisconsin scoring systems in young children with cystic fibrosis.

Authors:  Robert H Cleveland; Gregory S Sawicki; Catherine Stamoulis
Journal:  Pediatr Radiol       Date:  2015-05-29

4.  Brasfield and Wisconsin scoring systems have equal value as outcome assessment tools of cystic fibrosis lung disease.

Authors:  Robert H Cleveland; Catherine Stamoulis; Gregory Sawicki; Emma Kelliher; Evan J Zucker; Christopher Wood; David Zurakowski; Edward Lee
Journal:  Pediatr Radiol       Date:  2013-12-27

5.  Measurements of CFTR-mediated Cl- secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis.

Authors:  Marisa Sousa; Maria F Servidoni; Adriana M Vinagre; Anabela S Ramalho; Luciana C Bonadia; Verónica Felício; Maria A Ribeiro; Inna Uliyakina; Fernando A Marson; Arthur Kmit; Silvia R Cardoso; José D Ribeiro; Carmen S Bertuzzo; Lisete Sousa; Karl Kunzelmann; Antônio F Ribeiro; Margarida D Amaral
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

6.  Modified Chrispin-Norman chest radiography score for cystic fibrosis: observer agreement and correlation with lung function.

Authors:  P A de Jong; J A Achterberg; O A M Kessels; B van Ginneken; L Hogeweg; F J Beek; S W J Terheggen-Lagro
Journal:  Eur Radiol       Date:  2010-10-06       Impact factor: 5.315

7.  Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic Fibrosis.

Authors:  Justin E Ideozu; Xi Zhang; Amy Pan; Zainub Ashrafi; Katherine J Woods; Martin J Hessner; Pippa Simpson; Hara Levy
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

8.  Novel opportunities for CFTR-targeting drug development using organoids.

Authors:  Johanna F Dekkers; Cornelis K van der Ent; Jeffrey M Beekman
Journal:  Rare Dis       Date:  2013-11-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.